Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
Yohei Funakoshi,
Kimikazu Yakushijin,
Goh Ohji,
Wataru Hojo,
Hironori Sakai,
Marika Watanabe,
Akihito Kitao,
Yoshiharu Miyata,
Yasuyuki Saito,
Shinichiro Kawamoto,
Katsuya Yamamoto,
Mitsuhiro Ito,
Taiji Koyama,
Yoshinori Imamura,
Naomi Kiyota,
Hiroshi Matsuoka,
Yasuko Mori,
Hironobu Minami
Affiliations
Yohei Funakoshi
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Kimikazu Yakushijin
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Goh Ohji
Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Wataru Hojo
R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan
Hironori Sakai
R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan
Marika Watanabe
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Akihito Kitao
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Yoshiharu Miyata
BioResource Center, Kobe University Hospital, Kobe 650-0047, Japan
Yasuyuki Saito
Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Shinichiro Kawamoto
Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe 650-0017, Japan
Katsuya Yamamoto
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Mitsuhiro Ito
Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan
Taiji Koyama
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Yoshinori Imamura
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Naomi Kiyota
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Hiroshi Matsuoka
BioResource Center, Kobe University Hospital, Kobe 650-0047, Japan
Yasuko Mori
Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Hironobu Minami
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
